# VIB-KU Leuven Center for Cancer Biology

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/vib-ku-leuven-center-for-cancer-biology/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 78.1 |
| Citations | 1,139,088 |
| City | Leuven |
| Country | BE |
| Description | VIB-KU Leuven Center for Cancer Biology is a research organisation in Leuven, BE. OpenAlex records 4,094 works and 1,139,088 citations for it. 860 researchers list it as their most recent affiliation. |
| Homepage | https://vibcancer.be/ |
| OpenAlex ID | https://openalex.org/I4210092815 |
| Researchers | 860 |
| ROR ID | https://ror.org/00eyng893 |
| Type | facility |
| Works | 4,094 |

## University papers

- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death](https://scholariq.org/papers/vegf-is-a-modifier-of-amyotrophic-lateral-sclerosis-in-mice-and-humans-and/)
- [Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver](https://scholariq.org/papers/hippo-signaling-is-a-potent-in-vivo-growth-and-tumor-suppressor-pathway-in-the/)
- [Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy](https://scholariq.org/papers/inhibition-of-the-glycolytic-activator-pfkfb3-in-endothelium-induces-tumor/)
- [Gain of function of mutant p53 by coaggregation with multiple tumor suppressors](https://scholariq.org/papers/gain-of-function-of-mutant-p53-by-coaggregation-with-multiple-tumor-suppressors/)
- [International Cooperation to Enable the Diagnosis of All Rare Genetic Diseases](https://scholariq.org/papers/international-cooperation-to-enable-the-diagnosis-of-all-rare-genetic-diseases/)
- [The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin](https://scholariq.org/papers/the-plasminogen-activator-inhibitor-pai-1-controls-in-vivo-tumor-vascularization/)
- [VEGF: A modifier of the del22q11 (DiGeorge) syndrome?](https://scholariq.org/papers/vegf-a-modifier-of-the-del22q11-digeorge-syndrome/)
- [ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer](https://scholariq.org/papers/abca-transporter-gene-expression-and-poor-outcome-in-epithelial-ovarian-cancer/)
- [TMEM165 Deficiency Causes a Congenital Disorder of Glycosylation](https://scholariq.org/papers/tmem165-deficiency-causes-a-congenital-disorder-of-glycosylation/)
- [Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort](https://scholariq.org/papers/loss-of-i-tbk1-i-is-a-frequent-cause-of-frontotemporal-dementia-in-a-belgian/)
- [European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer](https://scholariq.org/papers/european-experts-consensus-brca-homologous-recombination-deficiency-testing-in/)

## University top topics

Showing 8 of 25.

- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)
- [Single-cell and spatial transcriptomics](https://scholariq.org/topics/single-cell-and-spatial-transcriptomics/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Cancer Cells and Metastasis](https://scholariq.org/topics/cancer-cells-and-metastasis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.